CSBio CSBio

X
[{"orgOrder":0,"company":"Thryv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Thryv Therapeutics Inc. Announces the Presentation of Scientific Data for Its Novel SGK1 Inhibitors at American Heart Association and San Antonio Breast Cancer Symposium","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Thryv Therapeutics"},{"orgOrder":0,"company":"Thryv Therapeutics","sponsor":"Investissement Qu\u00e9bec","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Thryv Therapeutics Announces Significant Progress Across all Programs within its SGK1 Inhibitor Portfolio and the Closing of a Convertible Note Financing with Investissement Qu\u00e9bec","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Thryv Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The proceeds will be used to immediately accelerate Thryv's portfolio programs including, LQT-1213 (islasertib), a potent and selective inhibitor of Serum Glucocorticoid inducible Kinase (SGK1), being developed for the treatment of Long QT Syndrome and Arrhythmias.

            Lead Product(s): Islasertib

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: LQT-1213

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Investissement Québec

            Deal Size: $5.0 million Upfront Cash: Undisclosed

            Deal Type: Financing June 06, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Thryv’s Serum and Glucocorticoid Regulated Kinase-1 inhibitors significantly reduced the cardiac action potential duration in re-engineered heart cells derived from patients with the major forms of Congenital Long QT syndrome and in a model of Drug Induced-QT Prolongation.

            Lead Product(s): Undisclosed

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 02, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY